Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPI | P34949 | 1/20 | 0.58 |
| ▸ | PGD | P52209 | 3/20 | 0.39 |
| ▸ | PGK1 | P00558 | 1/20 | 0.34 |
| ▸ | PGK2 | P07205 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9117419 | 1.00 | MPI (0.58) | MPIPGDPGK1PGK2 | |
| SCHEMBL987653 | 1.00 | MPI (0.58) | MPIPGDPGK1PGK2 | |
| Methoxyamine SCHEMBL6040178 | 0.93 | MPI (0.51) | MPIPGDPGK1PGK2 | |
| Methoxyamine SCHEMBL6040185 | 0.93 | MPI (0.51) | MPIPGDPGK1PGK2 | |
| Methoxyamine SCHEMBL6040149 | 0.93 | MPI (0.51) | MPIPGDPGK1PGK2 | |
| SCHEMBL3487364 | 0.90 | MPI (0.45) | MPI | |
| SCHEMBL5921670 | 0.90 | MPI (0.45) | MPI | |
| Mannose 6-Phosphate SCHEMBL9738212 | 0.87 | MPI (0.75) | MPIPGDPGK1PGK2 | |
| Mannose 6-Phosphate SCHEMBL1874195 | 0.87 | MPI (0.75) | MPIPGDPGK1PGK2 | |
| Mannose 6-Phosphate SCHEMBL9739836 | 0.87 | MPI (0.75) | MPIPGDPGK1PGK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3679065-A1 | SIGNALING AND ANTIGEN-PRESENTING BIFUNCTIONAL RECEPTORS (SABR) | California Institute of Technology (US) | 2020-07-15 | — | — | EP | disclosed |
| WO-2019051001-A1 | SIGNALING AND ANTIGEN-PRESENTING BIFUNCTIONAL RECEPTORS (SABR) | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2019-03-14 | — | — | WO | disclosed |
| EP-2305314-B1 | Remodelling and glycoconjugation of antibodies | RATIOPHARM GMBH (DE) | 2015-12-23 | — | — | EP | disclosed |
| EP-2760477-A1 | DI-ALIPHATIC SUBSTITUTED PEGYLATED LIPIDS | Alnylam Pharmaceuticals, Inc. (US) | 2014-08-06 | — | — | EP | disclosed |
| WO-2013049328-A9 | DI-ALIPHATIC SUBSTITUTED PEGYLATED LIPIDS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-12-27 | — | — | WO | disclosed |
| EP-2663548-A1 | PEGYLATED LIPIDS AND THEIR USE FOR DRUG DELIVERY | Alnylam Pharmaceuticals, Inc. (US) | 2013-11-20 | — | — | EP | disclosed |
| WO-2013049328-A1 | DI-ALIPHATIC SUBSTITUTED PEGYLATED LIPIDS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-04-04 | — | — | WO | disclosed |
| EP-2512449-A1 | METHODS AND COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS | The University of British Columbia (CA) | 2012-10-24 | — | — | EP | disclosed |
| WO-2012099755-A1 | PEGYLATED LIPIDS AND THEIR USE FOR DRUG DELIVERY | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-07-26 | — | — | WO | disclosed |
| WO-2012016184-A2 | METHODS AND COMPOSITIONS FOR DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | WO | disclosed |
| WO-2012016188-A2 | METHODS AND COMPOSITIONS FOR DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | WO | disclosed |
| WO-2011143230-A1 | METHODS AND COMPOSITIONS FOR DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS (US) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011100131-A9 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | ALNYLAM PHARMACUTICALS, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011100131-A2 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | ALNYLAM PHARMACUTICALS, INC. (US) | 2011-08-18 | — | — | WO | disclosed |
| WO-2011094580-A2 | CHELATED COPPER FOR USE IN THE PREPARATION OF CONJUGATED OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | WO | disclosed |
| WO-2011075656-A1 | METHODS AND COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-06-23 | — | — | WO | disclosed |
| WO-2009142822-A9 | 2-F MODIFIED RNA INTERFERENCE AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-01-14 | — | — | WO | disclosed |
| WO-2009142822-A2 | 2-F MODIFIED RNA INTERFERENCE AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| EP-1615611-A2 | iRNA CONJUGATES | Alnylam Pharmaceuticals Inc. (US) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004091515-A2 | iRNA CONJUGATES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2004-10-28 | — | — | WO | disclosed |